Beijing Luzhu Biotechnology Co (HKSE:02480) ROCE % : -20.91% (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beijing Luzhu Biotechnology Co's annualized ROCE % for the quarter that ended in Jun. 2024 was -20.91%.

Beijing Luzhu Biotechnology Co ROCE % Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co ROCE % Chart

Beijing Luzhu Biotechnology Co Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

ROCE %

-76.69

-82.97

-24.05

-16.35

Beijing Luzhu Biotechnology Co Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial			-14.90	-14.42	-29.96	-20.91	-11.78

Beijing Luzhu Biotechnology Co ROCE % Calculation

Beijing Luzhu Biotechnology Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-271.811	/	( ( (1195.075 - 105.098)	+	(1276.105 - 105.344) )	/ 2 )
	=	-271.811	/	( (1089.977	+	1170.761)	/ 2 )
	=	-271.811	/	1130.369
	=	-24.05 %

Beijing Luzhu Biotechnology Co's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-235.85	/	( ( (1276.105 - 105.344)	+	(1186.599 - 101.967) )	/ 2 )
	=	-235.85	/	( ( 1170.761	+	1084.632 )	/ 2 )
	=	-235.85	/	1127.6965
	=	-20.91 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Beijing Luzhu Biotechnology Co (HKSE:02480) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beijing Luzhu Biotechnology Co ROCE % Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Luzhu Biotechnology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN

Website

http://www.luzhubiotech.com

Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is its Core Product.

Executives

Kong Jian	2101 Beneficial owner
Zhang Yanping	2202 Interest of your spouse
Ma Jianan	2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si	2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo	2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo	2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
China Construction Bank Corporation	2201 Interest of corporation controlled by you
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Peng Ling	2201 Interest of corporation controlled by you
Ma Biao	2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co Headlines

No Headlines